Predicting cardiac proarrhythmic risk exclusively using automated patch-clamp data

Poster Description

Recent work by FDA and HESI CiPA working groups indicate that in vitro hERG, Nav1.5 and Cav1.2 potency data in addition to dynamic hERG kinetic data is required to accurately predict proarrhythmic risk. Below we explore two key challenges in exclusively using automated patch-clamp for risk prediction:

  1. Metrion has previously shown the ability to implement the difficult Milnes protocol on QPatch, but the challenges of producing full concentration response formats required for in silico models are unknown.
  2. Estimating accurate potencies for Cav1.2 inhibitors such as verapamil that match manual patch-clamp values and allow prediction of Multiple Ion Channel Effect (MICE) profiles with reduced proarrhythmia risk.
Download
Recommended Publications
Latest Publications
Development of Automated Electrophysiology Assays for the Characterisation of Inhibitors Against Human HCN Ion Channels

We demonstrate the generation and validation of a stable CHO-hHCN2 cell line used as a cellular tool in the successful development of hHCN2 automated electrophysiology screening assays.

Development of a High-Throughput Automated Electrophysiology Assay for Human Nav1.9 Inhibitor Screening

We have developed a robust high-throughput automated electrophysiology assay using a monoclonal CHO-hNav1.9 cellular reagent suitable for fully supporting a Nav1.9 discovery program.

View All
Metrion Biosciences is a contract research organisation (CRO) specialising in high-quality preclinical drug discovery services.
magnifier
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram